A phase 1a/b study of CB4211, a mitochondria based therapeutics (MBTs), in subjects with NASH and obesity with NAFLD.
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs CB 4211 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- 20 Nov 2017 New trial record
- 13 Nov 2017 According to a CohBar media release, the first mitochondrial based therapeutic in human trial is planned in 2018.